Pneumococcal Vaccines Market is Anticipated to Witness High Growth Owing to Increasing Government Initiatives

The pneumococcal vaccines market involves vaccines that help prevent pneumococcal disease. Pneumococcal disease refers to illnesses caused by the bacterium Streptococcus pneumoniae, including pneumonia, meningitis, and bacteremia. There are two main types of pneumococcal vaccines: pneumococcal conjugate vaccine (PCV) and pneumococcal polysaccharide vaccine (PPSV). PCV is recommended for children younger than 2 years, while PPSV is recommended for adults 65 years or older. These vaccines have significantly reduced rates of invasive pneumococcal disease (IPD) in both children and adults. The growing understanding among people about the importance of vaccinations for preventing deadly pneumococcal infections is driving the demand for pneumococcal vaccines. Moreover, governments across various countries have implemented national immunization programs which recommend pneumococcal vaccines, especially for children and elderly people.

Global pneumococcal vaccines market is estimated to be valued at USD 9.38 billion in 2025 and is expected to reach USD 13.29 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.1% from 2025 to 2032. 

Key Takeaways

Key players operating in the Pneumococcal Vaccines Pfizer Inc., Merck & Co., Inc., GlaxoSmithKline plc (GSK), Sanofi, CSL Limited, Serum Institute of India Pvt. Ltd., Vaxcyte, Inc., Astellas Pharma Inc., Panacea Biotec Ltd., Walvax Biotechnology Co., Ltd., Beijing Minhai Biotechnology Co., Ltd., Merck KGaA, Takeda Pharmaceutical Company Limited, AbbVie Inc., Novartis AG, Johnson & Johnson, Biovac, Bharat Biotech, Inovio Pharmaceuticals, Inc., Hilleman Laboratories Pvt. Ltd.

The Pneumococcal Vaccines Market Demand sees growth potential in Asia Pacific and Latin America, where vaccination coverage is below 70%, and from the need for higher valent vaccines covering additional serotypes of pneumonia.

Globally, Pfizer, Merck, and GSK are focused on expanding their manufacturing facilities and distribution networks across emerging markets. Sanofi is also investing in clinical trials to develop next-generation 10- and 15-valent pneumococcal conjugate vaccines.

Market Drivers

Increasing government initiatives - Many countries have introduced pneumococcal vaccines in their national immunization programs which has bolstered the demand. For instance, India introduced PCV vaccine in 2017 for children.

Growing awareness - Rising cases of pneumococcal pneumonia, septicemia, and meningitis has raised awareness about the importance of prevention through vaccination.

Market Restraints

High development costs - Developing new generation pneumococcal vaccines requires huge investments in R&D which adds to their high price.

Vaccine hesitancy - In developing nations, fear and misinformation about vaccine side effects has led to reluctance among some people. This impacts full immunization.

Segment Analysis

Pneumococcal vaccines market is segmented by type as pneumococcal conjugate vaccines (PCV13, PCV10) and pneumococcal polysaccharide vaccines (PPSV23). Pneumococcal conjugate vaccines dominate the market as they are recommended for routine use in children. PCV13 is recommended for all children younger than five years of age in the US. These vaccines provide protection against 13 types of pneumococcal bacteria as compared to PPSV23 vaccines which protect against 23 types of bacteria but are primarily recommended for adults aged 65 or older who are at increased risk.

Global Analysis

Regionally, North America dominates the pneumococcal vaccines market owing to higher immunization rates and availability of advanced vaccines. In the US, PCV13 vaccine is included in the routine pediatric immunization schedule. Europe is the second largest market due to large patient population and government support for vaccination programs. However, the Asia Pacific region is expected to show high growth during the forecast period due to rising healthcare investments, increasing disease awareness and improving access to vaccines. Initiatives by governments and non-profit organizations to boost immunization programs will support the growth of pneumococcal vaccines market in developing countries of Asia and Latin America.

Get This Report in Japanese Language -肺炎球菌ワクチン市場

Get This Report in Korean Language -폐렴구균 백신 시장

About Author:

Alice Mutum is a seasoned senior content editor at Coherent Market Insights, leveraging extensive expertise gained from her previous role as a content writer. With seven years in content development, Alice masterfully employs SEO best practices and cutting-edge digital marketing strategies to craft high-ranking, impactful content. As an editor, she meticulously ensures flawless grammar and punctuation, precise data accuracy, and perfect alignment with audience needs in every research report. Alice's dedication to excellence and her strategic approach to content make her an invaluable asset in the world of market insights.

(LinkedIn: www.linkedin.com/in/alice-mutum-3b247b137 )